GPP
RDHL

Great Point Partners’s Redhill Biopharma RDHL Stock Holding History

Great Point Partners’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-705
Closed -$5.16M – 36
2021
Q1 		$5.16M Buy
+705
New +$5.91M 1.07% 23

Other funds holding RDHL

DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM

Great Point Partners's RDHL Position: Q2 2021 in Review

Great Point Partners sold out of Redhill Biopharma (RDHL) in Q2 2021, closing a stake of 705 shares — an estimated $5.16M sold.

Great Point Partners first reported a position in RDHL in Q1 2021 and held it in 1 quarter. The position peaked at $5.16M in Q1 2021. 48 funds tracked by Wall St. Rank hold RDHL as of Q2 2021.

  • Great Point Partners reported no remaining Redhill Biopharma position as of Q2 2021 after selling out during the quarter.
  • Great Point Partners sold 705 Redhill Biopharma shares in Q2 2021, an estimated $5.16M.
  • Great Point Partners first reported a position in Redhill Biopharma in Q1 2021 and held it in 1 quarter.
  • Great Point Partners's Redhill Biopharma position peaked at $5.16M in Q1 2021.
  • 48 funds tracked by Wall St. Rank held Redhill Biopharma as of Q2 2021.

Based on Great Point Partners's 13F filing for Q2 2021, filed 16 Aug 2021.